Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least a four-point improvement in Pruritus NRS from baseline.On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), which will be presented at the Fall Clinical Dermatology Conference.
週五，Eli Lilly and Company（紐交所: LLY）公佈了Ebglyss（lebrikizumab）的第30億期ADapt研究的新結果，這將在秋季臨床皮膚病學會議上進行展示。
The results show that Ebglyss improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) Dupixent (dupilumab).
結果顯示，Ebglyss改善了先前接受賽諾菲安萬特（NASDAQ: SNY）/再生元製藥公司（NASDAQ: REGN）Dupixent（dupilumab）治療的中重度特應性皮炎（溼疹）患者的皮膚（包括手部和麪部）和瘙癢。
The study's primary endpoint was measured by at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks, which evaluates the extent and severity of the skin disease.
該研究的主要終點是在16周時，通過至少75%的溼疹面積和嚴重指數（EASI-75）評分改善程度，以評估皮膚疾病的範圍和嚴重程度。
Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least a four-point improvement in Pruritus NRS from baseline.
輔助終點在16周和24周時包括，調查員全球評估（IGA）評分爲清晰（0）或幾乎清晰（1）的皮膚，與基線相比至少降低兩分，以及自基線至少提高四分的瘙癢NRS。
With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with dupilumab achieved EASI-75.
使用Ebglyss後，在接受過dupilumab治療的患者中，57%的患者在第16周，60%的患者在第24周達到了EASI-75。
In addition, 46% of patients who were inadequate responders to dupilumab achieved EASI-75 response with Ebglyss at Week 16.
此外，對於對dupilumab反應不足的患者，有46%的患者在第16周通過Ebglyss實現了EASI-75的反應。
53% and 62% of ADapt patients who discontinued dupilumab and began treatment with Ebglyss also experienced itch relief (Pruritus NRS) with at least a four-point improvement from baseline at Week 16 and Week 24, respectively.
ADapt研究中有53%和62%的患者停用dupilumab並開始使用Ebglyss的患者在第16周和第24周分別也經歷了瘙癢緩解（瘙癢NRS），而且至少比基線提高了四分。
Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss.
在這項研究中，接受Ebglyss治療的患者在難治區域看到了改善。
52% treated with Ebglyss saw clear or almost clear face dermatitis at Week 24.
在第24周，52%接受Ebglyss治療的患者面部皮炎清晰或幾乎清晰。
Among patients with moderate-to-severe hand dermatitis at baseline, the modified total lesion-symptom score, which measures the extent and severity of hand dermatitis, decreased by 75 percent at Week 24.
在基線爲中度至重度手部皮炎的患者中，第24周修改後的總病變症狀評分下降了75% ，該評分衡量手部皮炎的程度和嚴重程度。
Less than 6% of patients treated with Ebglyss experienced an adverse event that led to treatment discontinuation.
接受Ebglyss治療的患者中不到6%經歷導致停止治療的不良事件。
Last month, the FDA approved Ebglyss, a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
上個月，FDA批准了Ebglyss，這是一種針對IL-13的靶向抑制劑，用於12歲及以上，體重至少88磅（40公斤）的成人和兒童，他們患有中度至重度無法通過局部處方療法有效控制的特應性皮炎（溼疹）。
Ebglyss was also approved in the European Union in 2023 and Japan in January 2024, with additional markets expected later this year.
Ebglyss還獲得了2023年在歐盟和2024年1月在日本批准，並預計後續市場將在今年晚些時候上市。
Price Action: LLY stock is up 0.32% at $894.15 at last check Friday.
股價表現：LLY股票在最後查看的星期五上漲了0.32%，報894.15美元。
Image via Shutterstock
圖片來自shutterstock。
- BKV's Integrated Operations Offer Value, Analyst Highlights Unique 'Closed-Loop' System And Growth Prospects
- BKV的綜合運營提供價值，分析師強調獨特的「閉環」系統和增長前景
譯文內容由第三人軟體翻譯。
